



# Iowa Department of Human Services

Kim Reynolds  
Governor

Adam Gregg  
Lt. Governor

Jerry R. Foxhoven  
Director

## INFORMATIONAL LETTER NO.1818-MC-FFS-D

**DATE:** August 17, 2017

**TO:** Iowa Medicaid Physicians, Dentists, Advanced Registered Nurse Practitioners, Therapeutically Certified Optometrists, Podiatrists, Pharmacies, Home Health Agencies, Rural Health Clinics, Clinics, Skilled Nursing Facilities, Intermediate Care Facilities, Nursing Facilities-Mental ILL, Federally Qualified Health Centers (FQHC), Indian Health Service, Maternal Health Centers, Certified Nurse Midwife, Community Mental Health, Family Planning, Residential Care Facilities, ICF/ID State and Community Based ICF/ID Providers

**APPLIES TO:** Managed Care, Fee-for-Service

**FROM:** Iowa Department of Human Services (DHS), Iowa Medicaid Enterprise (IME)

**RE:** Drugs for Rare Diseases under Outpatient Pharmacy Benefit

**EFFECTIVE:** July 1, 2017

[House File 653](#)<sup>1</sup> established a requirement for the Pharmaceutical and Therapeutics (P&T) Committee and the Drug Utilization Review (DUR) Commission to request and consider information from individuals who possess scientific or medical training with respect to drugs and biological products for rare diseases and drugs and biological products that are genetically targeted when making recommendations or determinations regarding beneficiary access.

Information will be requested by the IME for drugs and biological products identified as meeting the above criteria which may be reviewed at upcoming P&T and/or DUR meetings from individuals who possess scientific or medical training with respect to the drug, biological product, or rare disease.

The information request will be in the form of a Public Notification: Request for Comment, posted on the Preferred Drug List (PDL) website under the [Drugs for Rare Diseases](#)<sup>2</sup> link. Comment should be submitted to the contact indicated by the required response date, including a [conflict of interest disclosure form](#)<sup>3</sup>. Please continue to follow the established processes for providing oral public comment when attending the respective P&T and DUR meetings.

---

<sup>1</sup> <https://www.legis.iowa.gov/legislation/BillBook?ga=87&ba=HF%20653>

<sup>2</sup> [http://www.iowamedicaidpdl.com/drugs\\_rare\\_diseases\\_info](http://www.iowamedicaidpdl.com/drugs_rare_diseases_info)

<sup>3</sup> <http://www.iowamedicaidpdl.com/sites/default/files/ghs-files/miscellaneous-files/2012-09-17/coi-pt-speaker-9-07.pdf>

### **Process for Written Public Comment Submission for Drugs for Rare Diseases:**

- IME Public Notification: Request for Comment is posted to the PDL website.
- Listserv notification is sent by the IME.
- Individual prepares their public comment.
- Public comment is submitted to the appropriate IME contact (provided on the Public Notification) along with the conflict of interest disclosure form.
- Public comment is posted to the website and shared with the appropriate Committee(s).
- No response will be provided to the submitted public comment.

Please refer to the [P&T Committee](#)<sup>4</sup> and the [DUR Commission](#)<sup>5</sup> websites for information regarding meeting information. Please refer to the PDL website to sign up for the [listserv](#)<sup>6</sup>.

---

<sup>4</sup> <http://www.iowamedicaidpdl.com/sites/default/files/ghs-files/miscellaneous-files/2012-09-17/coi-pt-speaker-9-07.pdf>

<sup>5</sup> <https://iadur.org/>

<sup>6</sup> <http://www.iowamedicaidpdl.com/content/receive-email-notification>